VanEck Australian Floating Rate ETF vs GE HealthCare Technologies Inc. Common Stock — how do they compare? VanEck Australian Floating Rate ETF trades at $50.93 (market cap $11.37B), while GE HealthCare Technologies Inc. Common Stock trades at $68.97 (market cap $31.07B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 2.7× VanEck Australian Floating Rate ETF's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while VanEck Australian Floating Rate ETF pays none. Which is the better fit depends on your goals.
| FLOT | GEHC | |
|---|---|---|
Market Cap | $11.37B | $31.07B |
Volume | 2,190,809 | 3,443,020 |
Sector | Fixed Income | Health |
52-Week High | $51.07 | $88.16 |
52-Week Low | $50.72 | $59.48 |
Typical Hold Time | 23 Days | — |
Enterprise Value | — | $39.53B |
Dividend Yield | — | 0.23% |
Signals from Pluang's Aura AI — not financial advice
FLOT trades at $50.95 with minimal daily movement (+0.02%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The ETF benefits from floating rate exposure amid Fed tightening, with recent dividends of $0.17-$0.18 paid through October 2026. News highlights concentration risk with 47% bank exposure but positions FLOT as a cash substitute in rising rate environments.
Outlook remains tied to Fed policy, with floating rates offering yield advantage if hikes persist. Key risks include bank sector concentration and rate reversal. Analyst sentiment is cautious due to technical weakness but acknowledges strategic utility for barbell portfolios alongside duration assets.
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Trailing returns across standard periods
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →